Literature DB >> 25481790

PARP inhibitors in BRCA mutation-associated ovarian cancer.

Andrew Clamp1, Gordon Jayson2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25481790     DOI： 10.1016/S1470-2045(14)71172-6

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  10 in total

1.  A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer.

Authors:  Paz Polak; Jaegil Kim; Lior Z Braunstein; Rosa Karlic; Nicholas J Haradhavala; Grace Tiao; Daniel Rosebrock; Dimitri Livitz; Kirsten Kübler; Kent W Mouw; Atanas Kamburov; Yosef E Maruvka; Ignaty Leshchiner; Eric S Lander; Todd R Golub; Aviad Zick; Alexandre Orthwein; Michael S Lawrence; Rajbir N Batra; Carlos Caldas; Daniel A Haber; Peter W Laird; Hui Shen; Leif W Ellisen; Alan D D'Andrea; Stephen J Chanock; William D Foulkes; Gad Getz
Journal:  Nat Genet       Date:  2017-08-21       Impact factor: 38.330

2.  Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study.

Authors:  H S Han; V Diéras; M Robson; M Palácová; P K Marcom; A Jager; I Bondarenko; D Citrin; M Campone; M L Telli; S M Domchek; M Friedlander; B Kaufman; J E Garber; Y Shparyk; E Chmielowska; E H Jakobsen; V Kaklamani; W Gradishar; C K Ratajczak; C Nickner; Q Qin; J Qian; S P Shepherd; S J Isakoff; S Puhalla
Journal:  Ann Oncol       Date:  2018-01-01       Impact factor: 32.976

3.  ADP-Ribosylation Levels and Patterns Correlate with Gene Expression and Clinical Outcomes in Ovarian Cancers.

Authors:  Lesley B Conrad; Ken Y Lin; Tulip Nandu; Bryan A Gibson; Jayanthi S Lea; W Lee Kraus
Journal:  Mol Cancer Ther       Date:  2019-10-08       Impact factor: 6.261

4.  Synergistic suppressive effect of PARP-1 inhibitor PJ34 and HDAC inhibitor SAHA on proliferation of liver cancer cells.

Authors:  Bin-Yong Liang; Min Xiong; Gui-Bao Ji; Er-Lei Zhang; Zun-Yi Zhang; Ke-Shuai Dong; Xiao-Ping Chen; Zhi-Yong Huang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-07-31

5.  Olaparib.

Authors:  S C Goulooze; A F Cohen; R Rissmann
Journal:  Br J Clin Pharmacol       Date:  2015-10-24       Impact factor: 4.335

Review 6.  PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.

Authors:  Robert D Morgan; Andrew R Clamp; D Gareth R Evans; Richard J Edmondson; Gordon C Jayson
Journal:  Cancer Chemother Pharmacol       Date:  2018-02-20       Impact factor: 3.333

7.  Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma.

Authors:  Toni Rose Jue; Kyoko Nozue; Ashleigh J Lester; Swapna Joshi; Lisette B W Schroder; Shane P Whittaker; Sheri Nixdorf; Robert W Rapkins; Mustafa Khasraw; Kerrie L McDonald
Journal:  J Transl Med       Date:  2017-03-17       Impact factor: 5.531

8.  DEBIO 1143, an IAP inhibitor, reverses carboplatin resistance in ovarian cancer cells and triggers apoptotic or necroptotic cell death.

Authors:  Benoît Thibault; Ludivine Genre; Augustin Le Naour; Clothilde Broca; Eliane Mery; Grégoire Vuagniaux; Jean Pierre Delord; Norbert Wiedemann; Bettina Couderc
Journal:  Sci Rep       Date:  2018-12-14       Impact factor: 4.379

9.  Tumor suppressive effect of PARP1 and FOXO3A in gastric cancers and its clinical implications.

Authors:  See-Hyoung Park; Kyu Yun Jang; Min Jae Kim; Sarah Yoon; Yuna Jo; So Mee Kwon; Kyoung Min Kim; Keun Sang Kwon; Chan Young Kim; Hyun Goo Woo
Journal:  Oncotarget       Date:  2015-12-29

10.  Incorporation of Peptides Targeting EGFR and FGFR1 into the Adenoviral Fiber Knob Domain and Their Evaluation as Targeted Cancer Therapies.

Authors:  Hanni Uusi-Kerttula; Mateusz Legut; James Davies; Rachel Jones; Emma Hudson; Louise Hanna; Richard J Stanton; John D Chester; Alan L Parker
Journal:  Hum Gene Ther       Date:  2015-05       Impact factor: 4.793
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.